Dupixent CTCL

Federal Dupixent lymphoma lawsuits are consolidated in MDL No. 3180 before Judge Zahid N. Quraishi in the District of New Jersey, centralized June 4, 2026. Plaintiffs allege Sanofi and Regeneron failed to warn that cutaneous T-cell lymphoma (CTCL) can mimic eczema and that Dupixent may mask cancer symptoms, delaying diagnosis. Twenty-six cases were pending as of July 1, 2026; no court has ruled on the merits and no settlement exists.

MDL No. 3180 centralized June 4, 2026 in D.N.J. before Judge Zahid N. Quraishi. The litigation remains in early pretrial posture with coordinated discovery and leadership appointments pending; no bellwether schedule has been set.

Dupixent approved March 2017 with nine indications. No lymphoma or malignancy warning on FDA label as of August 2026. FDA evaluating potential safety events for CTCL; published studies report statistical association but authors note causation unestablished. Comprehensive review identified 124 patients with lymphoproliferative disorders post-dupilumab, median 5 months to biopsy, 39.05% advanced stage. No national prescription volume or total exposed population data available in sources.

• District of New Jersey

  MDL 3180 centralized federal Dupixent CTCL cases before Judge Zahid N. Quraishi on June 4, 2026. JPML transferred 15 cases from 12 federal districts at formation. Approximately 28 cases on file as of mid-August 2026. No merits rulings, no settlement.

• Georgia

  Case filings heavily concentrated here, per source describing 'heavily concentrated in Georgia' as driver for MDL consolidation. One of originating jurisdictions among 12 federal districts at MDL 3180 formation.

• Tennessee

  First Dupixent wrongful death lawsuit filed in Middle District of Tennessee (Oct. 2025), predating MDL formation. One-year statute of limitations: Tenn. Code Ann. § 28-3-104. Early litigation incubator for CTCL/PTCL claims.

• Alabama

  Originating jurisdiction among cases JPML transferred into MDL 3180 at formation. Per source, Alabama filings included in initial 15-case transfer.

• New York

  Regeneron Pharmaceuticals facility in Rensselaer, NY — active FDA inspection history with documented issues (last FDA action March 22, 2024). U.S. ingredient manufacturing site for dupilumab.

• Ireland

  Two facilities with Dupixent supply chain: Genzyme Ireland Limited (Waterford, last FDA action Jan. 17, 2025) and Regeneron Ireland DAC (Limerick, last FDA action March 14, 2023). Both have documented FDA inspection issues.

• Germany

  Sanofi-aventis Deutschland GmbH (Frankfurt am Main) — Dupixent manufacturing facility with documented FDA inspection issues (last action Jan. 16, 2025).

• France

  Sanofi Winthrop Industrie (Le Trait) — Dupixent manufacturing facility with documented FDA inspection issues (last action April 25, 2023).

No MDL established as of March 2026. Individual cases filed in federal courts including M.D. Tenn. (Richardson, response deadline Jan. 7, 2026 per Magistrate Judge Alistair Newbern). Primary accrual theories: (1) date of CTCL diagnosis; (2) date of discovery of Dupixent-CTCL link. FDA placed Dupixent on potential serious risks list March 2025; label still lacks CTCL warning per November 2025 reports. Discovery rule critical in most jurisdictions given latency period (August 2024 JAAD study showed 4.1x increased risk, median diagnosis >1 year post-initiation). Federal preemption defenses likely; no federal recall. Screen for: minimum 1 month Dupixent use; CTCL, mycosis fungoides, or Sézary syndrome diagnosis; no prior lymphoma/leukemia.